In particular, inhibition of the EGFR family by monoclonal antibodies such as trastuzumab or cetuximab impairs the PI3K pathway and promotes FOXO3a activity [122], while reconstitution of active FOXO3a results in sensitization of resistant cancer cells to EGFR/HER2 inhibitors like lapatinib and gefitinib [121]. This evidence concerns the gene FOXO3 and cancer.